{"entity":{"id":"reliance","kind":"trial","name":"RELIANCE","aka":[],"tldr":"The trial that made relma-cel the first CAR-T developed and manufactured in China to be approved, with three quarters of patients responding.","summary":"59 patients treated (Cancer Medicine 2021): objective response 75.9%, complete response 51.7%, with grade 3 or higher cytokine release syndrome in about 5% and neurotoxicity in about 3%, a favourable profile consistent with the 4-1BB construct shared with lisocabtagene maraleucel. Basis of NMPA approval in September 2021.","status":"positive","asOf":"2026-09-10","links":[{"label":"Cancer Med 2021","url":"https://doi.org/10.1002/cam4.3686"}],"tags":["china"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["car-t"],"targets":["cd19"],"drugs":["relmacabtagene-autoleucel"],"companies":["jw-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-ying-cancer-med"],"journals":[],"dependsOn":[],"notes":[],"phase":"2","setting":"Relapsed or refractory large B-cell lymphoma after two or more lines, China: single-arm pivotal study of relmacabtagene autoleucel at two dose levels","sponsor":"JW Therapeutics","result":"ORR 75.9%, CR 51.7%.","yearReported":2021,"enrolled":59,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective response rate","primary":true,"unit":"%","arms":[{"name":"Relma-cel (both dose levels)","n":59,"value":75.9}],"source":"https://doi.org/10.1002/cam4.3686"}]},"route":"/trials/reliance/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"relmacabtagene-autoleucel","kind":"drug","name":"Relmacabtagene autoleucel","route":"/drugs/relmacabtagene-autoleucel/"}],"company":[{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","route":"/companies/jw-therapeutics/"}],"paper":[{"id":"paper-ying-cancer-med","kind":"paper","name":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China","route":"/key-papers/paper-ying-cancer-med/"}],"idea":[{"id":"idea-reg-in-vivo-cart-off-the-shelf-vial","kind":"idea","name":"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma","route":"/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/"},{"id":"idea-reg-non-viral-cart-manufacturing","kind":"idea","name":"Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route","route":"/ideas/idea-reg-non-viral-cart-manufacturing/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}